rs35942089

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_024996.7(GFM1):​c.127A>G​(p.Asn43Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.011 in 1,611,068 control chromosomes in the GnomAD database, including 135 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N43S) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0089 ( 16 hom., cov: 33)
Exomes 𝑓: 0.011 ( 119 hom. )

Consequence

GFM1
NM_024996.7 missense

Scores

1
4
12

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:10

Conservation

PhyloP100: 8.87

Publications

6 publications found
Variant links:
Genes affected
GFM1 (HGNC:13780): (G elongation factor mitochondrial 1) Eukaryotes contain two protein translational systems, one in the cytoplasm and one in the mitochondria. Mitochondrial translation is crucial for maintaining mitochondrial function and mutations in this system lead to a breakdown in the respiratory chain-oxidative phosphorylation system and to impaired maintenance of mitochondrial DNA. This gene encodes one of the mitochondrial translation elongation factors. Its role in the regulation of normal mitochondrial function and in different disease states attributed to mitochondrial dysfunction is not known. [provided by RefSeq, Jul 2008]
LXN (HGNC:13347): (latexin) This gene encodes the only known protein inhibitor of zinc-dependent metallocarboxypeptidases. The encoded protein, latexin, downregulates the population size of hematopoietic stem cells. This protein is found to be downregulated in cancer cells because of promoter hypermethylation. [provided by RefSeq, Jul 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.008831739).
BP6
Variant 3-158645674-A-G is Benign according to our data. Variant chr3-158645674-A-G is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 137462.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00889 (1354/152320) while in subpopulation NFE AF = 0.014 (953/68030). AF 95% confidence interval is 0.0133. There are 16 homozygotes in GnomAd4. There are 647 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 16 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GFM1NM_024996.7 linkc.127A>G p.Asn43Asp missense_variant Exon 2 of 18 ENST00000486715.6 NP_079272.4

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GFM1ENST00000486715.6 linkc.127A>G p.Asn43Asp missense_variant Exon 2 of 18 1 NM_024996.7 ENSP00000419038.1

Frequencies

GnomAD3 genomes
AF:
0.00890
AC:
1354
AN:
152202
Hom.:
16
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00181
Gnomad AMI
AF:
0.0164
Gnomad AMR
AF:
0.00452
Gnomad ASJ
AF:
0.0237
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.00870
Gnomad FIN
AF:
0.00933
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0140
Gnomad OTH
AF:
0.00765
GnomAD2 exomes
AF:
0.00961
AC:
2416
AN:
251432
AF XY:
0.00990
show subpopulations
Gnomad AFR exome
AF:
0.00172
Gnomad AMR exome
AF:
0.00309
Gnomad ASJ exome
AF:
0.0204
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0109
Gnomad NFE exome
AF:
0.0138
Gnomad OTH exome
AF:
0.00912
GnomAD4 exome
AF:
0.0112
AC:
16352
AN:
1458748
Hom.:
119
Cov.:
30
AF XY:
0.0115
AC XY:
8325
AN XY:
725894
show subpopulations
African (AFR)
AF:
0.00150
AC:
50
AN:
33430
American (AMR)
AF:
0.00369
AC:
165
AN:
44716
Ashkenazi Jewish (ASJ)
AF:
0.0193
AC:
505
AN:
26106
East Asian (EAS)
AF:
0.0000504
AC:
2
AN:
39672
South Asian (SAS)
AF:
0.00762
AC:
657
AN:
86190
European-Finnish (FIN)
AF:
0.0126
AC:
674
AN:
53412
Middle Eastern (MID)
AF:
0.00243
AC:
14
AN:
5764
European-Non Finnish (NFE)
AF:
0.0123
AC:
13675
AN:
1109170
Other (OTH)
AF:
0.0101
AC:
610
AN:
60288
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
764
1527
2291
3054
3818
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
454
908
1362
1816
2270
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00889
AC:
1354
AN:
152320
Hom.:
16
Cov.:
33
AF XY:
0.00869
AC XY:
647
AN XY:
74466
show subpopulations
African (AFR)
AF:
0.00180
AC:
75
AN:
41576
American (AMR)
AF:
0.00451
AC:
69
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.0237
AC:
82
AN:
3466
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5184
South Asian (SAS)
AF:
0.00870
AC:
42
AN:
4826
European-Finnish (FIN)
AF:
0.00933
AC:
99
AN:
10616
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.0140
AC:
953
AN:
68030
Other (OTH)
AF:
0.00757
AC:
16
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.488
Heterozygous variant carriers
0
67
134
201
268
335
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0125
Hom.:
53
Bravo
AF:
0.00732
TwinsUK
AF:
0.0132
AC:
49
ALSPAC
AF:
0.0101
AC:
39
ESP6500AA
AF:
0.00250
AC:
11
ESP6500EA
AF:
0.0145
AC:
125
ExAC
AF:
0.00982
AC:
1192
Asia WGS
AF:
0.00144
AC:
5
AN:
3478
EpiCase
AF:
0.0122
EpiControl
AF:
0.0100

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 Benign:4
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease.

Nov 24, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

May 18, 2021
Pars Genome Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 12, 2019
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

not specified Benign:3
Mar 29, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency, gene associated with combined oxidative phosphorylation deficiency

Jan 31, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: GFM1 c.127A>G (p.Asn43Asp) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0096 in 251432 control chromosomes, predominantly at a frequency of 0.014 within the Non-Finnish European subpopulation in the gnomAD database, including 14 homozygotes, suggesting a benign role of the gene. c.127A>G has been reported in the literature in individuals affected with unspecified mitochondrial disorder without evidence for causality (Wang_2011). This report does not provide unequivocal conclusions about association of the variant with Hepatoencephalopathy Due To Combined Oxidative Phosphorylation Defect Type 1. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign (n=5), likely benign (n=2). Based on the evidence outlined above, the variant was classified as benign.

Jan 11, 2014
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

not provided Benign:3
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Aug 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

GFM1: BP4, BS1, BS2

Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.37
T
BayesDel_noAF
Benign
-0.30
CADD
Benign
22
DANN
Uncertain
0.98
DEOGEN2
Benign
0.025
T;T;.
Eigen
Benign
-0.0059
Eigen_PC
Uncertain
0.23
FATHMM_MKL
Pathogenic
1.0
D
LIST_S2
Uncertain
0.94
D;D;D
MetaRNN
Benign
0.0088
T;T;T
MetaSVM
Benign
-0.81
T
MutationAssessor
Uncertain
2.1
M;.;M
PhyloP100
8.9
PrimateAI
Benign
0.43
T
PROVEAN
Benign
-0.31
N;N;N
REVEL
Benign
0.23
Sift
Benign
0.65
T;T;T
Sift4G
Benign
0.33
T;T;T
Vest4
0.68
ClinPred
0.056
T
GERP RS
5.4
Varity_R
0.34
gMVP
0.91
Mutation Taster
=99/1
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs35942089; hg19: chr3-158363463; COSMIC: COSV108045339; COSMIC: COSV108045339; API